Compare Abeona Therapeutics Inc (ABEO) vs First Solar, Inc. (FSLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs First Solar, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while First Solar, Inc. trades at $224.63 (market cap $24.47B). The key difference: First Solar, Inc. is far larger — about 65.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | FSLR | |
|---|---|---|
Market Cap | $373.32M | $24.47B |
Sector | Health | Technology |
52-Week High | $7.23 | $318.30 |
52-Week Low | $4.17 | $160.84 |
Enterprise Value | $228.22M | $22.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
First Solar (FSLR) trades at $227.72, up 1.4% with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with $5.22B revenue, 30.73% net margin, and positive cash flow trends. Recent earnings beat expectations in Q1 2026 but missed in previous quarters. Multiple class action lawsuits create significant headwinds, though Deutsche Bank recently upgraded the stock citing valuation discount.
The stock presents a valuation opportunity with P/E of 15.06 below industry averages, but legal risks and technical weakness suggest cautious optimism. Analyst consensus price target of $272.20 implies 19.5% upside potential, though investors must weigh strong profitability against ongoing litigation concerns and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
